Search Results
-
FILTER BY DATEAll Time
-
-
FILTER BY RELEVANCEMost Relevant
-
-
FILTER BY CONTENT TYPEAll Content Types
-
The reality is that we simply do not know how efficacious most drugs really are.
Health care hawks in Congress may seize on painkillerVioxx"s woes to push for major changes in the Food and Drug Administration"s drug approval process.
Testimony in defense of the FDA, which has come under attack recently for its handling of drug safety.
The American tort liability systemworks badly when it gets infected by junk science.
It would be too easy, in an effort to cut costs, to constrict the pipeline that is producing one new wonder drug after another.
Looming on the horizon is a political battle over direct-to-consumer advertising of prescription drugs.
An examination of Cox-2 class drugs for assessing Merck's decision to withdraw Vioxx.
The recent verdict in a case involving the pain reliever Vioxx demonstrates how junk science can corrupt drug litigation.
